CN102266488A - Medicament for treating leucoderma - Google Patents
Medicament for treating leucoderma Download PDFInfo
- Publication number
- CN102266488A CN102266488A CN2011102132571A CN201110213257A CN102266488A CN 102266488 A CN102266488 A CN 102266488A CN 2011102132571 A CN2011102132571 A CN 2011102132571A CN 201110213257 A CN201110213257 A CN 201110213257A CN 102266488 A CN102266488 A CN 102266488A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- root
- medicine
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses a medicament for treating leucoderma. The medicament is prepared from the following Chinese herbal medicines in part by weight: 100 to 150 parts of glossy privet fruit, 100 to 150 parts of yerbadetajo herba ecliptae, 40 to 80 parts of incised notopterygium rhizome, 30 to 50 parts of semen psoraleae, 30 to 60 parts of prepared polygonum multiflorum thunb., 20 to 40 parts of white mustard seed (stir-fried), 80 to 120 parts of notoginseng root, 100 to 150 parts of Szechuan lovage rhizome, 50 to 100 parts of suberect spatholobus stem, 50 to 100 parts of tree peony bark, 40 to 80 parts of chaff flower root, 40 to 80 parts of nutgrass galingale rhizome, 40 to 80 parts of officinal magnolia bark, 100 to 150 parts of gambir plant, 100 to 150 parts of thinleaf milkwort root-bark, 30 to 60 parts of tribulus fruit, 30 to 60 parts of angelica dahurica, 30 to 60 parts of divaricate saposhnikovia root, 50 to 100 parts of cicada slough, 40 to 80 parts of common bletilla pseudobulb, 40 to 80 parts of densefruit pittany root-bark, 40 to 80 parts of platycodon root, 40 to 80 parts of pubescent angelica root, 50 to 100 parts of tuber fleeceflower stem, 50 to 100 parts of acanthopanax root bark, 50 to 100 parts of Chinese taxillus twig, 10 to 20 parts of pyrite and 30 to 60 parts of liquoric root. The medicament is a pure Chinese medicinal preparation, which can treat the leucoderma effectively and does not have toxic or side effect.
Description
Technical field
The present invention relates to the leukodermic medicine of a kind of treatment, relating in particular to a kind of is the medicament of feedstock production with the Chinese herbal medicine.
Background technology
Traditional Chinese medicine of vitiligo claims vitiligo, is a kind of depigmentation dermatoses, clinical branch second phase, two classes and two types.Vitiligo is one of universally acknowledged dermatosis chronic disease, can betide any age, any race, and sickness rate is 0.3～3.8%.Along with the quickening of people's rhythm of life, leukodermic sickness rate is in rising trend.Though vitiligo does not have obvious influence to health, general also no conscious sympton has a strong impact on attractive in appearancely, makes the patient produce inferiority complex and stress, even produces mental sickness.Modern medicine confirms that also patients with vitiligo obviously descends to ultraviolet defence capability, should receive much concern.
Doctor trained in Western medicine is not having effective therapy aspect the treatment vitiligo now, and the medicine of treatment is very few, and toxic and side effects is bigger in addition, makes the patient be reluctant to accept.The traditional Chinese medical science has prescription miscellaneous to the treatment vitiligo, raw materials used pharmacopoeia class, and dosage has than big difference, and effect is also different.Effectively treatment even elimination vitiligo are the problems that medical circle is constantly inquired into always.
Summary of the invention
Technical problem to be solved by this invention provides the leukodermic medicine of a kind of treatment, and this medicine is a kind of pure Chinese medicinal preparation that can effectively effect a radical cure vitiligo and have no side effect.
Administer opinion according to China differential diagnosis in tcm opinion, vitiligo is by feelings will internal injury, and depression of liver-QI is felt the heresy of rheumatism again and fought in skin, disharmony between QI and blood functional activity of QI being not smooth in addition, and blood does not nourish skin, and deficiency of the liver and kindey also is one of cause of disease.Dispersing the stagnated live-QI to relieve the stagnation of QI is taked in treatment, blood circulation promoting and blood stasis dispelling, and dredging the meridian, nourishing blood to suppress the hyperactive liver, nourishing the liver and kidney, microcirculation improvement promotes melanin regeneration.Adopt the method for oral administration and externally, treating both the principal and secondary aspects of a disease is to reach the purpose of thorough radical cure.
In order to solve the problems of the technologies described above, the present invention takes following technical scheme:
The leukodermic medicine of a kind of treatment is characterized in that it is the medicament of being made by following raw materials by weight proportions: 100～150 parts of Fructus Ligustri Lucidi, 100～150 parts of ecliptae herbas, 40～80 parts of Rhizoma Et Radix Notopterygiis, 30～50 parts of Fructus Psoraleaes, 30～60 parts of Radix Polygoni Multiflori Preparata, 20～40 parts of Semen Sinapis Albaes (stir-fry), 80～120 parts of Radix Notoginseng, 100～150 parts of Rhizoma Chuanxiongs, 50～100 parts of Caulis Spatholobis, 50～100 parts of Cortex Moutans, 40～80 parts of Radix Achyranthis Bidentataes, 40～80 parts of Rhizoma Cyperis, 40～80 parts of Cortex Magnoliae Officinalis, 100～150 parts of Ramulus Uncariae Cum Uncis, 100～150 parts of Radix Polygalaes, 30～60 parts of Fructus Atriplicis Sibiricaees, 30～60 parts of the Radixs Angelicae Dahuricae, 30～60 parts of Radix Saposhnikoviaes, 50～100 parts of Periostracum Cicadaes, 40～80 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 40～80 parts of Cortex Dictamni, 40～80 parts of Radix Platycodoniss, 40～80 parts of Radix Angelicae Pubescentiss, 50～100 parts of Caulis Polygoni Multiflori, 50～100 parts of Cortex Acanthopanciss, 50～100 parts of Herba Taxillis, 10～20 parts of Pyritums, 30～60 parts in Radix Glycyrrhizae.
Wherein, 120 parts of preferred Fructus Ligustri Lucidi, 120 parts of ecliptae herbas, 60 parts of Rhizoma Et Radix Notopterygiis, 40 parts of Fructus Psoraleaes, 50 parts of Radix Polygoni Multiflori Preparata, 30 parts of Semen Sinapis Albaes (stir-fry), 100 parts of Radix Notoginseng, 120 parts of Rhizoma Chuanxiongs, 80 parts of Caulis Spatholobis, 80 parts of Cortex Moutans, 60 parts of Radix Achyranthis Bidentataes, 60 parts of Rhizoma Cyperis, 60 parts of Cortex Magnoliae Officinalis, 120 parts of Ramulus Uncariae Cum Uncis, 120 parts of Radix Polygalaes, 50 parts of Fructus Atriplicis Sibiricaees, 50 parts of the Radixs Angelicae Dahuricae, 50 parts of Radix Saposhnikoviaes, 80 parts of Periostracum Cicadaes, 60 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 60 parts of Cortex Dictamni, 60 parts of Radix Platycodoniss, 60 parts of Radix Angelicae Pubescentiss, 60 parts of Caulis Polygoni Multiflori, 80 parts of Cortex Acanthopanciss, 80 parts of Herba Taxillis, 15 parts of Pyritums, 40 parts in Radix Glycyrrhizae.
Described medicine is a medicine for external use, and pharmacy type is a tincture.Take following steps to make:
(a) with each crude drug mix homogeneously of described weight, under normal pressure, used the boiling water steamed enough 15 minutes, shone down enough 6 hours at 20～35 ℃, repeat to grind to form granule after steaming, the solarization once;
(b) adding mass fraction is 5000 parts of 75% ethanol, places the sealing of cool dark place to preserve 90 days, crosses the elimination medicinal residues, promptly gets tincture after the sterilization.
Perhaps, described medicine is an oral medicine, and pharmacy type is a pill, perhaps powder, perhaps capsule, perhaps sublimed preparation, perhaps tablet.Take following steps to make:
(a) with each crude drug mix homogeneously of described weight, under normal pressure, use enough 15 minutes of boiling water steamed, shone down enough 6 hours, repeat steaming, shine once back grind into powder at 20～35 ℃;
(b) described powder is crossed 100 mesh sieves, make pill, perhaps powder, perhaps capsule, perhaps sublimed preparation, perhaps tablet.
Beneficial effect of the present invention is Radix Notoginseng in the side, Rhizoma Chuanxiong, Caulis Spatholobi, Cortex Moutan, Radix Achyranthis Bidentatae, blood circulation promoting and blood stasis dispelling; Fructus Ligustri Lucidi, ecliptae herba, Fructus Psoraleae, Radix Polygoni Multiflori Preparata, Semen Sinapis Albae, Pyritum promotes melanin new life, nourishes rough skin; Pseudobulbus Bletillae (Rhizoma Bletillae) convergence disease controlling; The Radix Angelicae Dahuricae, Radix Saposhnikoviae, Periostracum Cicadae is induced sweat, nourishes rough skin; Ramulus Uncariae Cum Uncis, Radix Polygalae, Fructus Atriplicis Sibiricae, Rhizoma Cyperi, Cortex Magnoliae Officinalis, dispersing the stagnated live-QI to relieve the stagnation of QI, circulation of qi promoting, blood circulation depending on qi flow is to help the curative effect of activating blood and removing stasis drug; Cortex Acanthopancis, Herba Taxilli, nourishing the liver and kidney; Rhizoma Et Radix Notopterygii is used for disease above the waist, and Radix Angelicae Pubescentis is used for lower part of the body disease; Caulis Spatholobi, Caulis Polygoni Multiflori mediation pathway has the merit of nourshing blood and promoting blood circulation concurrently; The Radix Platycodonis medicine carrying is up, makes drug effect reach the top diseased region; The Radix Achyranthis Bidentatae priming of invigorating blood circulation is descending, makes drug effect reach the bottom diseased region, has the merit of nourishing the liver and kidney concurrently; The Cortex Dictamni heat clearing and damp drying; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription makes the property of medicine unified, makes the drug effect focus of going directly.This recipe ingredient is rigorous, and the division of labor is clear and definite, in monarch Each answers the purpose intended the prescription each component division of labor clear and definite, nonirritant and toxic and side effects can make the medicine focus of go directly, can effect a radical cure and are difficult for recurring.
The specific embodiment
Among the following embodiment, every part is 1 gram.
Embodiment one:
The crude drug weight proportion is: 120 parts of Fructus Ligustri Lucidi, 120 parts of ecliptae herbas, 60 parts of Rhizoma Et Radix Notopterygiis, 40 parts of Fructus Psoraleaes, 50 parts of Radix Polygoni Multiflori Preparata, 30 parts of Semen Sinapis Albaes (stir-fry), 100 parts of Radix Notoginseng, 120 parts of Rhizoma Chuanxiongs, 80 parts of Caulis Spatholobis, 80 parts of Cortex Moutans, 60 parts of Radix Achyranthis Bidentataes, 60 parts of Rhizoma Cyperis, 60 parts of Cortex Magnoliae Officinalis, 120 parts of Ramulus Uncariae Cum Uncis, 120 parts of Radix Polygalaes, 50 parts of Fructus Atriplicis Sibiricaees, 50 parts of the Radixs Angelicae Dahuricae, 50 parts of Radix Saposhnikoviaes, 80 parts of Periostracum Cicadaes, 60 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 60 parts of Cortex Dictamni, 60 parts of Radix Platycodoniss, 60 parts of Radix Angelicae Pubescentiss, 60 parts of Caulis Polygoni Multiflori, 80 parts of Cortex Acanthopanciss, 80 parts of Herba Taxillis, 15 parts of Pyritums, 40 parts in Radix Glycyrrhizae.
Embodiment two:
The crude drug weight proportion is: 100 parts of Fructus Ligustri Lucidi, 100 parts of ecliptae herbas, 40 parts of Rhizoma Et Radix Notopterygiis, 30 parts of Fructus Psoraleaes, 30 parts of Radix Polygoni Multiflori Preparata, 20 parts of Semen Sinapis Albaes (stir-fry), 80 parts of Radix Notoginseng, 100 parts of Rhizoma Chuanxiongs, 50 parts of Caulis Spatholobis, 50 parts of Cortex Moutans, 40 parts of Radix Achyranthis Bidentataes, 40 parts of Rhizoma Cyperis, 40 parts of Cortex Magnoliae Officinalis, 100 parts of Ramulus Uncariae Cum Uncis, 100 parts of Radix Polygalaes, 30 parts of Fructus Atriplicis Sibiricaees, 60 parts of the Radixs Angelicae Dahuricae, 60 parts of Radix Saposhnikoviaes, 100 parts of Periostracum Cicadaes, 80 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 80 parts of Cortex Dictamni, 80 parts of Radix Platycodoniss, 80 parts of Radix Angelicae Pubescentiss, 100 parts of Caulis Polygoni Multiflori, 100 parts of Cortex Acanthopanciss, 100 parts of Herba Taxillis, 20 parts of Pyritums, 60 parts in Radix Glycyrrhizae.
Embodiment three:
The crude drug weight proportion is: 150 parts of Fructus Ligustri Lucidi, 150 parts of ecliptae herbas, 80 parts of Rhizoma Et Radix Notopterygiis, 50 parts of Fructus Psoraleaes, 60 parts of Radix Polygoni Multiflori Preparata, 40 parts of Semen Sinapis Albaes (stir-fry), 120 parts of Radix Notoginseng, 150 parts of Rhizoma Chuanxiongs, 100 parts of Caulis Spatholobis, 100 parts of Cortex Moutans, 80 parts of Radix Achyranthis Bidentataes, 80 parts of Rhizoma Cyperis, 80 parts of Cortex Magnoliae Officinalis, 150 parts of Ramulus Uncariae Cum Uncis, 150 parts of Radix Polygalaes, 60 parts of Fructus Atriplicis Sibiricaees, 30 parts of the Radixs Angelicae Dahuricae, 30 parts of Radix Saposhnikoviaes, 50 parts of Periostracum Cicadaes, 40 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 40 parts of Cortex Dictamni, 40 parts of Radix Platycodoniss, 40 parts of Radix Angelicae Pubescentiss, 50 parts of Caulis Polygoni Multiflori, 50 parts of Cortex Acanthopanciss, 50 parts of Herba Taxillis, 10 parts of Pyritums, 30 parts in Radix Glycyrrhizae.
Embodiment four: the medicine for external use manufacture method
Press arbitrary proportioning among the embodiment one to three, finish through following operating procedure:
(a) with each crude drug mix homogeneously of described weight, under normal pressure, used the boiling water steamed enough 15 minutes, shone down enough 6 hours at 20～35 ℃, repeat to grind to form granule after steaming, the solarization once;
(b) adding mass fraction is 5000 parts of 75% ethanol, places the sealing of cool dark place to preserve 90 days, crosses the elimination medicinal residues, promptly gets tincture after the sterilization.
Embodiment five: the oral medicine manufacture method
Press arbitrary proportioning among the embodiment one to three, finish through following operating procedure:
(a) with each crude drug mix homogeneously of described weight, under normal pressure, use enough 15 minutes of boiling water steamed, shone down enough 6 hours, repeat steaming, shine once back grind into powder at 20～35 ℃;
(b) described powder is crossed 100 mesh sieves, make pill, perhaps powder, perhaps capsule, perhaps sublimed preparation, perhaps tablet.
Embodiment six:
Follow the tracks of patient's 68 examples, male's 42 examples, women's 26 examples, 9～68 years old age.Patient's head, trunk extremity, brothers all have morbidity, all adopt this medicine, dip in medicine with cotton swab during treatment and smear behind the affected part affected part friction 30 seconds, to promote medicinal liquid to absorb, every day for oral administration 3 times, each 4 restrain, medication two all state of an illness are all controlled, progressive stage, no longer develop, stable disease, one or two month pigment new life, merge gradually later on, local little itching do not have other untoward reaction, has no side effect.Four to 11 month cure rates reach 92%, do not have recurrence.
Embodiment seven:
Patient Liu, woman, 48 years old, people from Dingzhou, Hebei.Trunk, head, shank all have morbidity, and pathological changes is very much not waited to palm by coin, and the affected part pigment takes off mistake fully, become irregular type, belong to complete depigmentation vitiligo of progressive stage, go to a doctor and do not cure in how tame hospital.Use this medicine, smear medicine every day 3 times, massaged 30 seconds at every turn, each oral 4 grams, every day 3 times, the state of an illness is effectively controlled after two weeks, and PD stops, pigment occurs in 40 days visible white maculas, merge gradually later on, skin recovered normal in eight months, visible small amount of coloring matter calmness, consolidate drug withdrawal in two months, do not see recurrence.
Embodiment eight:
Patient Zhu, man, 10 years old, people from Huiyang, Guangdong.Patient's head has one of the big vitiligo of palm, and ill 2 years, card was seen affected part completeness depigmentation, and the diseased region hair is silvery white in color.Use this medicine, external every day 4 times rubbed 30 seconds at every turn, oral every day 3 times, each 2 grams.Stable disease after three weeks, visible diseased region melanin new life after 35 days, pigment merges after four months, and hair is blackening thereupon also, is almost recovered after nine months, and the affected part is more black slightly than normal skin, consolidates after two months thoroughly recovery from illness.
Claims (6)
1. the leukodermic medicine of treatment is characterized in that it is the medicament of being made by following raw materials by weight proportions: 100～150 parts of Fructus Ligustri Lucidi, 100～150 parts of ecliptae herbas, 40～80 parts of Rhizoma Et Radix Notopterygiis, 30～50 parts of Fructus Psoraleaes, 30～60 parts of Radix Polygoni Multiflori Preparata, 20～40 parts of Semen Sinapis Albaes (stir-fry), 80～120 parts of Radix Notoginseng, 100～150 parts of Rhizoma Chuanxiongs, 50～100 parts of Caulis Spatholobis, 50～100 parts of Cortex Moutans, 40～80 parts of Radix Achyranthis Bidentataes, 40～80 parts of Rhizoma Cyperis, 40～80 parts of Cortex Magnoliae Officinalis, 100～150 parts of Ramulus Uncariae Cum Uncis, 100～150 parts of Radix Polygalaes, 30～60 parts of Fructus Atriplicis Sibiricaees, 30～60 parts of the Radixs Angelicae Dahuricae, 30～60 parts of Radix Saposhnikoviaes, 50～100 parts of Periostracum Cicadaes, 40～80 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 40～80 parts of Cortex Dictamni, 40～80 parts of Radix Platycodoniss, 40～80 parts of Radix Angelicae Pubescentiss, 50～100 parts of Caulis Polygoni Multiflori, 50～100 parts of Cortex Acanthopanciss, 50～100 parts of Herba Taxillis, 10～20 parts of Pyritums, 30～60 parts in Radix Glycyrrhizae.
2. the leukodermic medicine of treatment as claimed in claim 1 is characterized in that it is the medicament of being made by following raw materials by weight proportions: 120 parts of Fructus Ligustri Lucidi, 120 parts of ecliptae herbas, 60 parts of Rhizoma Et Radix Notopterygiis, 40 parts of Fructus Psoraleaes, 50 parts of Radix Polygoni Multiflori Preparata, 30 parts of Semen Sinapis Albaes (stir-fry), 100 parts of Radix Notoginseng, 120 parts of Rhizoma Chuanxiongs, 80 parts of Caulis Spatholobis, 80 parts of Cortex Moutans, 60 parts of Radix Achyranthis Bidentataes, 60 parts of Rhizoma Cyperis, 60 parts of Cortex Magnoliae Officinalis, 120 parts of Ramulus Uncariae Cum Uncis, 120 parts of Radix Polygalaes, 50 parts of Fructus Atriplicis Sibiricaees, 50 parts of the Radixs Angelicae Dahuricae, 50 parts of Radix Saposhnikoviaes, 80 parts of Periostracum Cicadaes, 60 parts of Pseudobulbus Bletillae (Rhizoma Bletillae), 60 parts of Cortex Dictamni, 60 parts of Radix Platycodoniss, 60 parts of Radix Angelicae Pubescentiss, 60 parts of Caulis Polygoni Multiflori, 80 parts of Cortex Acanthopanciss, 80 parts of Herba Taxillis, 15 parts of Pyritums, 40 parts in Radix Glycyrrhizae.
3. as claim 1 or the leukodermic medicine of 2 described treatments, it is characterized in that described medicine is a medicine for external use, pharmacy type is a tincture.
4. the leukodermic medicine of treatment as claimed in claim 3 is characterized in that described tincture takes following steps to make:
(a) with each crude drug mix homogeneously of described weight, under normal pressure, used the boiling water steamed enough 15 minutes, shone down enough 6 hours at 20～35 ℃, repeat to grind to form granule after steaming, the solarization once;
(b) adding mass fraction is 5000 parts of 75% ethanol, places the sealing of cool dark place to preserve 90 days, crosses the elimination medicinal residues, promptly gets tincture after the sterilization.
5. as claim 1 or the leukodermic medicine of 2 described treatments, it is characterized in that described medicine is an oral medicine, pharmacy type is a pill, perhaps powder, perhaps capsule, perhaps sublimed preparation, perhaps tablet.
6. the leukodermic medicine of treatment as claimed in claim 5 is characterized in that described pharmacy type takes following steps to make:
(a) with each crude drug mix homogeneously of described weight, under normal pressure, use enough 15 minutes of boiling water steamed, shone down enough 6 hours, repeat steaming, shine once back grind into powder at 20～35 ℃;
(b) described powder is crossed 100 mesh sieves, make pill, perhaps powder, perhaps capsule, perhaps sublimed preparation, perhaps tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102132571A CN102266488B (en) | 2011-07-15 | 2011-07-15 | Medicament for treating leucoderma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102132571A CN102266488B (en) | 2011-07-15 | 2011-07-15 | Medicament for treating leucoderma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102266488A true CN102266488A (en) | 2011-12-07 |
| CN102266488B CN102266488B (en) | 2012-12-05 |
Family
ID=45049068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102132571A Active CN102266488B (en) | 2011-07-15 | 2011-07-15 | Medicament for treating leucoderma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102266488B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526285A (en) * | 2012-03-22 | 2012-07-04 | 常熟市虞山绿茶有限公司 | Chinese medicine composition for treating vitiligo |
| CN103007080A (en) * | 2012-11-25 | 2013-04-03 | 展继军 | Medicine for curing psora |
| CN103055172A (en) * | 2012-12-03 | 2013-04-24 | 展继军 | Chinese medicinal composition for treating leucoderma |
| CN103623174A (en) * | 2013-12-04 | 2014-03-12 | 宋明柱 | Leucoderma capsule |
| CN105833150A (en) * | 2016-05-17 | 2016-08-10 | 商皓 | Externally-applied medicine for treating leucoderma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049374A (en) * | 2007-04-25 | 2007-10-10 | 王家成 | Oral liquid for treating leucoderma, and preparation method |
| CN101618149A (en) * | 2008-06-30 | 2010-01-06 | 刘芳 | Chinese medicament for curing vitiligo |
-
2011
- 2011-07-15 CN CN2011102132571A patent/CN102266488B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101049374A (en) * | 2007-04-25 | 2007-10-10 | 王家成 | Oral liquid for treating leucoderma, and preparation method |
| CN101618149A (en) * | 2008-06-30 | 2010-01-06 | 刘芳 | Chinese medicament for curing vitiligo |
Non-Patent Citations (1)
| Title |
|---|
| 《甘肃中医》 20080331 查日煌 中医药治疗白癜风的新进展 57－61 1－6 第21卷, 第三期 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526285A (en) * | 2012-03-22 | 2012-07-04 | 常熟市虞山绿茶有限公司 | Chinese medicine composition for treating vitiligo |
| CN103007080A (en) * | 2012-11-25 | 2013-04-03 | 展继军 | Medicine for curing psora |
| CN103007080B (en) * | 2012-11-25 | 2014-10-01 | 展继军 | Medicine for curing psora |
| CN103055172A (en) * | 2012-12-03 | 2013-04-24 | 展继军 | Chinese medicinal composition for treating leucoderma |
| CN103623174A (en) * | 2013-12-04 | 2014-03-12 | 宋明柱 | Leucoderma capsule |
| CN105833150A (en) * | 2016-05-17 | 2016-08-10 | 商皓 | Externally-applied medicine for treating leucoderma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102266488B (en) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101450141B (en) | Medicine for treating alopecia | |
| CN101757569A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis and cerebral infarction and preparation method thereof | |
| CN103071128B (en) | Externally-applied plaster for curing dysmenorrhea | |
| CN102284051B (en) | Medicine for treating chloasma | |
| CN102266488B (en) | Medicament for treating leucoderma | |
| CN100460008C (en) | Chinese medicine composition for treating cancer | |
| CN102274252B (en) | Stauntonvine external applied preparation for treating rheumatoid diseases and preparation method thereof | |
| CN104225450A (en) | Traditional Chinese medicine for treating depression | |
| CN101926857A (en) | Traditional Chinese medicinal liniment for treating vitiligo | |
| CN1883642A (en) | Medicine for treating mammary glands hyperplasia | |
| CN101057922A (en) | Traditional Chinese medicine preparation for treating vitiligo | |
| CN103550688A (en) | Traditional Chinese medicine (TCM) composition for treating palpitation | |
| CN102698214A (en) | Traditional Chinese medicine for treating migraine and preparation method thereof | |
| CN1286500C (en) | Medication for treating numbness of the muscles and painful joints | |
| CN102813746B (en) | Traditional Chinese medicine composition for treating numbness of fingers | |
| CN106581299B (en) | Traditional Chinese medicine composition for improving kidney qi deficiency of middle-aged and old people and application thereof | |
| CN105194227A (en) | Traditional Chinese medicine pills for treating leucoderma and preparation method of traditional Chinese medicine pills | |
| CN103055172A (en) | Chinese medicinal composition for treating leucoderma | |
| CN101940624A (en) | Chinese medicinal lotion for treating vitiligo | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN102743580B (en) | Traditional Chinese medicine pill for treating vitligo | |
| CN102430026A (en) | Medicine for removing macula | |
| CN101843717B (en) | Chinese medicament for treating coronary disease | |
| CN101843758B (en) | Chinese medicament for treating coronary disease | |
| CN104306480A (en) | Yao nationality drug composition for treating coronary heart disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |